We are live on ! Find out more
GNMK

GenMark Diagnostics, Inc
GNMK

Delisted

GNMK was delisted on the 21st of April, 2021.

78 hedge funds and large institutions have $402M invested in GenMark Diagnostics, Inc in 2014 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 35 increasing their positions, 21 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 21

25% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 8

0% more funds holding

Funds holding: 7878 (0)

22% less capital invested

Capital invested by funds: $516M → $402M (-$114M)

Holders
78
Holders Change
Holders Change %
0%
% of All Funds
2.25%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
10
Increased
35
Reduced
21
Closed
8
Calls
$171K
Puts
Net Calls
+$171K
Net Calls Change
+$173K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$62.5M +$789K +63,516 +1%
PI
2
Putnam Investments
Massachusetts
$51.4M -$489K -39,367 -0.8%
Jennison Associates
3
Jennison Associates
New York
$40.6M -$300K -24,111 -0.6%
JP Morgan Chase
4
JP Morgan Chase
New York
$33.6M +$10.3M +831,753 +33%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$26.4M +$59.6K +4,800 +0.2%
Artisan Partners
6
Artisan Partners
Wisconsin
$20.5M -$2.92M -235,346 -10%
Massachusetts Financial Services
7
Massachusetts Financial Services
Massachusetts
$20.1M +$1.89M +152,160 +8%
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$15.6M -$537K -43,196 -3%
Vanguard Group
9
Vanguard Group
Pennsylvania
$10.4M +$1.81M +145,610 +16%
BFA
10
BlackRock Fund Advisors
California
$10M +$437K +35,159 +4%
CRC
11
Curi RMB Capital
Illinois
$9.84M +$435K +35,011 +4%
VAM
12
Visium Asset Management
New York
$9.6M +$600K +48,324 +5%
Bank of America
13
Bank of America
North Carolina
$9.45M +$2.03M +163,358 +21%
CCM
14
Camber Capital Management
Massachusetts
$9.03M -$521K -41,900 -4%
CCM
15
Cadian Capital Management
New York
$8.7M +$1.24M +100,000 +13%
JHIU
16
Janus Henderson Investors US
Colorado
$6.47M +$2.78M +223,947 +52%
State Street
17
State Street
Massachusetts
$5.33M +$294K +23,623 +5%
Ameriprise
18
Ameriprise
Minnesota
$5.22M +$3.13M +252,139 +92%
Northern Trust
19
Northern Trust
Illinois
$4.65M -$550K -44,278 -9%
OM
20
Opaleye Management
Massachusetts
$4.32M +$5.41M +435,000 New
BIT
21
BlackRock Institutional Trust
California
$4.11M +$41.4K +3,328 +0.8%
Alyeska Investment Group
22
Alyeska Investment Group
Illinois
$3.8M +$1.61M +129,856 +51%
Millennium Management
23
Millennium Management
New York
$3.16M +$3.63M +292,482 +1,170%
New York State Common Retirement Fund
24
New York State Common Retirement Fund
New York
$2.02M
Geode Capital Management
25
Geode Capital Management
Massachusetts
$1.97M +$59.8K +4,816 +2%

GNMK Hedge Fund Activity: Q1 2014 in Review

78 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in GenMark Diagnostics, Inc (GNMK) for Q1 2014, worth a combined $402M — down 22% from $516M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new GNMK positions and 8 closed out — a net gain of 2 holders — while 35 added to existing stakes and 21 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $10.3M. The largest seller was PointState Capital, exiting entirely with an estimated $3.97M sold.

  • 78 institutional investors held GenMark Diagnostics, Inc (GNMK) as of Q1 2014, unchanged from Q4 2013.
  • Funds reported $402M of GenMark Diagnostics, Inc stock for Q1 2014, down 22% quarter-over-quarter.
  • 10 funds opened new GenMark Diagnostics, Inc positions in Q1 2014 and 8 closed out, a net change of +2 holders.
  • The largest GenMark Diagnostics, Inc buyer in Q1 2014 was JP Morgan Chase, an estimated $10.3M added.
  • The largest GenMark Diagnostics, Inc seller in Q1 2014 was PointState Capital, an estimated $3.97M sold.

Based on aggregated 13F filings for Q1 2014.